Clinical Trial Update: Cinacalcet Study to Reach Kidney Disease Outcomes Quality Initiative (K/DOQI) Levels [Phase 2]

View source ↗

Summary

Phase 2 trial of cinacalcet in end-stage renal disease sponsored by Amgen has completed. The study aimed to reach Kidney Disease Outcomes Quality Initiative (K/…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease

Drugs mentioned

• SENSIPAR (CINACALCET HYDROCHLORIDE)

Snippet

Sponsor: Amgen | Conditions: End Stage Renal Disease | Phase 2 | Status: COMPLETED